Merck's Tulisokibart Shows Promising Results in Phase 2b Trial for Hidradenitis Suppurativa

Merck has announced positive results from its Phase 2b trial of tulisokibart, an investigational treatment for moderate to severe hidradenitis suppurativa. The study met its primary endpoint, demonstrating a significant improvement in the Hidradenitis Suppurativa Clinical Response 50 at week 16 for patients treated with high-dose and medium-dose tulisokibart regimens.

Specifically, 72% of patients in the high-dose group and 64% in the medium-dose group achieved HiSCR50, representing a 37% and 29% improvement over the placebo group, respectively. The low-dose group showed an exploratory analysis with a 52% response rate, a 17% improvement over placebo.

The results also showed comparable safety between tulisokibart and placebo groups in this trial, with similar rates of adverse events occurring across treatment groups.